Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 83Metastatic Castration Resistant Prostate Cancer 9Breast Neoplasms 9Neoplasms 8Neoplasm Metastasis 8Prostatic Neoplasms, Castration-Resistant 6Prostate Cancer Metastatic 4Castration-resistant Prostate Cancer 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Triple Negative Breast Neoplasms 2Non-metastatic Castration-resistant Prostate Cancer 2Metastatic Castration-resistant Prostate Cancer 2Metastatic Castration-Resistant Prostate Cancer 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Ureteral Diseases 1Seizures 1Recurrent Endometrial Endometrioid Adenocarcinoma 1Prostate Carcinoma Metastatic to the Bone 1Primary Dysautonomias 1Primary Breast Cancer ER+ve 1Pharmacokinetics of MDV3100 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-metastatic, Hormone naïve Prostate Cancer 1Non-metastatic Prostate Cancer 1Metastatic Progressive Castration-resistant Prostate Cancer 1

Interventions

radium Ra 223 dichloride 2niraparib 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Prostate Carcinoma Metastatic to the Bone × enzalutamide × Clear all
NCT02507570 2019-03-19

Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis

Carolina Research Professionals, LLC

Phase 2 Completed
40 enrolled
Genitourinary

Prostate Carcinoma Metastatic to the Bone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡